Stock Analysis

MedinCell And Two More Euronext Paris Growth Stocks With High Insider Ownership

ENXTPA:VU
Source: Shutterstock

As the French market navigates through a period of political uncertainty with upcoming elections, investors are closely monitoring shifts in economic indicators and market sentiments. In such times, growth stocks with high insider ownership can offer a unique appeal, as these insiders may have a deeper commitment to the company's long-term success.

Top 10 Growth Companies With High Insider Ownership In France

NameInsider OwnershipEarnings Growth
VusionGroup (ENXTPA:VU)13.5%25.2%
Groupe OKwind Société anonyme (ENXTPA:ALOKW)24.8%30.8%
Adocia (ENXTPA:ADOC)12.1%59.8%
Icape Holding (ENXTPA:ALICA)30.2%26.1%
Arcure (ENXTPA:ALCUR)21.4%42.4%
La Française de l'Energie (ENXTPA:FDE)20.1%31.9%
S.M.A.I.O (ENXTPA:ALSMA)17.3%35.2%
Munic (ENXTPA:ALMUN)29.4%150%
WALLIX GROUP (ENXTPA:ALLIX)19.8%101.6%
MedinCell (ENXTPA:MEDCL)16.4%74.9%

Click here to see the full list of 22 stocks from our Fast Growing Euronext Paris Companies With High Insider Ownership screener.

We're going to check out a few of the best picks from our screener tool.

MedinCell (ENXTPA:MEDCL)

Simply Wall St Growth Rating: ★★★★★☆

Overview: MedinCell S.A. is a French pharmaceutical company specializing in the development of long-acting injectable medications across multiple therapeutic areas, with a market capitalization of approximately €410.34 million.

Operations: The company generates revenue primarily from its pharmaceutical segment, totaling €11.95 million.

Insider Ownership: 16.4%

Earnings Growth Forecast: 74.9% p.a.

MedinCell, a French pharmaceutical company, reported a decrease in sales and revenue for the fiscal year ending March 2024 but reduced its net loss from the previous year. Recent clinical trials have shown mixed results, with its F14 drug not meeting primary endpoints but showing improvements in secondary measures. Despite high volatility in its share price, MedinCell is anticipated to grow revenues at 43.7% annually and become profitable within three years, driven by promising developments like the TEV-‘749 schizophrenia treatment and collaborations with major industry players like AbbVie.

ENXTPA:MEDCL Ownership Breakdown as at Jul 2024
ENXTPA:MEDCL Ownership Breakdown as at Jul 2024

OVH Groupe (ENXTPA:OVH)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: OVH Groupe S.A. is a global provider of public and private cloud services, shared hosting, and dedicated server solutions, with a market capitalization of approximately €1.13 billion.

Operations: The company generates revenue through three primary segments: public cloud (€169.01 million), private cloud (€589.61 million), and web cloud (€185.43 million).

Insider Ownership: 10.5%

Earnings Growth Forecast: 103.7% p.a.

OVH Groupe, a French cloud services provider, is navigating its growth trajectory with significant insider ownership. The company recently introduced advanced server technology in the U.S., enhancing its product offerings and competitive edge. Despite a slower revenue growth rate of 10.9% per year compared to faster market segments, OVH is expected to become profitable within three years, reflecting above-average market growth potential. However, its return on equity is projected to remain low at 1.7%, and share price volatility remains high, posing challenges for stability-seeking investors.

ENXTPA:OVH Ownership Breakdown as at Jul 2024
ENXTPA:OVH Ownership Breakdown as at Jul 2024

VusionGroup (ENXTPA:VU)

Simply Wall St Growth Rating: ★★★★★★

Overview: VusionGroup S.A. specializes in offering digitalization solutions for commerce across Europe, Asia, and North America, with a market capitalization of approximately €2.15 billion.

Operations: The company's primary revenue of €801.96 million is generated from the installation and maintenance of electronic shelf labels.

Insider Ownership: 13.5%

Earnings Growth Forecast: 25.2% p.a.

VusionGroup S.A., a French growth company with significant insider ownership, has shown robust financial performance with a substantial increase in sales to €801.96 million and net income to €79.77 million for the year ended December 31, 2023. Despite its highly volatile share price over the past three months, VusionGroup's earnings are expected to grow by 25.2% annually, outpacing the French market's forecast of 10.9%. Analysts predict a potential stock price increase of 46.5%, reflecting confidence in its future performance amidst recent strategic corporate activities including special shareholder meetings and international conference presentations.

ENXTPA:VU Earnings and Revenue Growth as at Jul 2024
ENXTPA:VU Earnings and Revenue Growth as at Jul 2024

Where To Now?

Searching for a Fresh Perspective?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Valuation is complex, but we're helping make it simple.

Find out whether VusionGroup is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com